Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

BACKGROUND Hormone therapy for early prostate cancer has demonstrated an improvement in clinical and pathological variables, but not always an improvement in overall survival. We performed a systematic review of both adjuvant and neo-adjuvant hormone therapy combined with surgery or radiotherapy in localised or locally advanced prostate cancer. OBJECTIVES The objective of this review was to undertake a systematic review and, if possible, a meta-analysis of neo-adjuvant and adjuvant hormone therapy in localised or locally advanced prostate cancer. SEARCH STRATEGY We searched MEDLINE (1966-2006), EMBASE, The Cochrane Library, Science Citation Index, LILACS, and SIGLE for relevant randomised trials. Handsearching of appropriate publications was also undertaken. SELECTION CRITERIA Randomised or quasi-randomised controlled trials of patients with localised or locally advanced prostate cancer, that is, stages T1-T4, any N, M0, comparing neo-adjuvant or adjuvant hormonal deprivation in combination with primary therapy (radical radiotherapy or radical prostatectomy) versus primary therapy alone were included in this review. DATA COLLECTION AND ANALYSIS Data were extracted from eligible studies and assessed for quality, and included information on study design, participants, interventions, and outcomes. Comparable data were pooled together for meta-analysis with intention-to treat principle. MAIN RESULTS Men with prostate cancer have different clinical outcomes based on their risk (T1-T2, T3-T4, PSA levels and Gleason score). However, the majority of studies included in this review did not report results by risk groups; therefore, it was not possible to perform sub-group analysis. Neo-adjuvant hormonal therapy prior to prostatectomy did not improve overall survival (OR 1.11, 95% CI 0.67 to 1.85, P = 0.69). However, there was a significant reduction in the positive surgical margin rate (OR 0.34, 95% CI 0.27 to 0.42, P < 0.00001) and a significant improvement in other pathological variables such as lymph node involvement, pathological staging and organ confined rates. There was a borderline significant reduction of disease recurrence rates (OR 0.74, 95% CI 0.55 to 1.0, P = 0.05), in favour of treatment. The use of longer duration of neo-adjuvant hormones, that is either 6 or 8 months prior to prostatectomy, was associated with a significant reduction in positive surgical margins (OR 0.56, 95% CI 0.39 to 0.80, P = 0.002). In one study, neo-adjuvant hormones prior to radiotherapy significantly improved overall survival for Gleason 2 to 6 patients; although, in two studies, there was no improvement in disease-specific survival (OR 0.99, 95% CI 0.75 to 1.32, P = 0.97). However, there was a significant improvement in both clinical disease-free survival (OR 1.86, 95% CI 1.93 to 2.40, P < 0.00001) and biochemical disease-free survival (OR 1.93, 95% CI 1.45 to 2.56, P < 0.00001). Adjuvant androgen deprivation following prostatectomy did not significantly improve overall survival at 5 years (OR 1.50, 95% CI 0.79 to 2.85, P = 0.2); although one study reported a significant disease-specific survival advantage with adjuvant therapy (P = 0.001). In addition, there was a significant improvement in disease-free survival at both 5 years (OR 3.73, 95%CI 2.30 to 6.03, P < 0.00001) and 10 years (OR 2.06, 95% CI 1.34 to 3.15, P = 0.0009). Adjuvant therapy following radiotherapy resulted in a significant overall survival gain apparent at 5 (OR 1.46, 95% CI 1.17 to 1.83, P = 0.0009) and 10 years (OR 1.44, 95% CI 1.13 to 1.84, P = 0.003); although there was significant heterogeneity (P = 0.09 and P = 0.07, respectively). There was also a significant improvement in disease-specific survival (OR 2.10, 95% CI 1.53 to 2.88, P = 0.00001) and disease-free survival (OR 2.53, 95% CI 2.05 to 3.12, P < 0.00001) at 5 years. AUTHORS' CONCLUSIONS Hormone therapy combined with either prostatectomy or radiotherapy is associated with significant clinical benefits in patients with local or locally advanced prostate cancer. Significant local control may be achieved when given prior to prostatectomy or radiotherapy, which may improve patient's quality of life. When given adjuvant to these primary therapies, hormone therapy, not only provides a method for local control, but there is also evidence for a significant survival advantage. However, hormone therapy is associated with significant side effects, such as hot flushes and gynaecomastia, as well as cost implications. The decision to use hormone therapy should, therefore, be taken at a local level, between the patient, clinician and policy maker, taking into account the clinical benefits, toxicity and cost. More research is needed to guide the choice, the duration, and the schedule of hormonal deprivation therapy, and the impact of long-term hormone therapy with regard to toxicity and the patient's quality of life.

[1]  R. Nagle,et al.  Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. , 1996, The Journal of urology.

[2]  P. Dunscombe,et al.  A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. , 2003, Urologic oncology.

[3]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[4]  Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863. , 2002, European urology.

[5]  J. Simard,et al.  Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first‐line therapy , 1993, Cancer.

[6]  R. Montironi,et al.  Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study. , 1999, Pathology, research and practice.

[7]  Y. Ohashi,et al.  Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. , 1999, Urology.

[8]  Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group. , 1998, The Journal of urology.

[9]  A. Schned,et al.  Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials. , 1998, The Journal of urology.

[10]  J. Kao,et al.  Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma , 2003, Cancer.

[11]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[12]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[13]  W. Fair,et al.  Incidence and clinical significance of false-negative sextant prostate biopsies. , 1998, The Journal of urology.

[14]  T. Tammela,et al.  A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. , 2002, European urology.

[15]  S. Rosenthal,et al.  RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate , 2000 .

[16]  Debruyne Fm,et al.  Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. , 2000 .

[17]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[18]  R. Abrams,et al.  Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in locally advanced prostate carcinoma: the emerging role of psa in the assessment of outcome , 1993 .

[19]  J. Srigley,et al.  Pathologic Effects of Neoadjuvant Cyproterone Acetate on Nonneoplastic Prostate, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: A Detailed Analysis of Radical Prostatectomy Specimens From a Randomized Trial , 2002, The American journal of surgical pathology.

[20]  D. Grignon,et al.  Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Wirth,et al.  Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. , 2003, European urology.

[22]  T. H. van der Kwast,et al.  Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. , 1999, Urology.

[23]  M. Wirth,et al.  Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer , 2006, BJU international.

[24]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[25]  D. Prezioso,et al.  Role of Neoadjuvant Treatment in Clinically Confined Prostate Cancer , 1998, European Urology.

[26]  A. V. von Eschenbach,et al.  Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. , 1988, International journal of radiation oncology, biology, physics.

[27]  D. Wood,et al.  Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .

[28]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[29]  T. Tammela,et al.  Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. , 2004, Urology.

[30]  J. Hugosson,et al.  Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. , 2000, Urology.

[31]  A. Fortin,et al.  The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. , 2004, The Journal of urology.

[32]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Srigley,et al.  Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. , 1996, The Journal of urology.

[34]  V. Reuter,et al.  Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues , 2000, Cancer.

[35]  J. Hugosson,et al.  Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment , 2000, The Prostate.

[36]  P. Rubin,et al.  Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. , 2002, International journal of radiation oncology, biology, physics.

[37]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[38]  M. Gleave,et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.

[39]  W. Sause,et al.  Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31) , 1996 .

[40]  D. Joseph,et al.  Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  J. Hugosson,et al.  The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. , 1996, European urology.

[42]  R. Stock,et al.  Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. , 2002, International journal of radiation oncology, biology, physics.

[43]  G. Muto,et al.  Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. , 2001, Urology.

[44]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[45]  M. Gleave,et al.  Neoadjuvant hormone therapy: the Canadian trials. , 2000, Molecular urology.

[46]  J. Goméz,et al.  Neoadjuvant hormonal therapy: the Canadian experience. , 1997, Urology.

[47]  J. Chin,et al.  Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. , 2003, The Journal of urology.

[48]  J. Goméz,et al.  Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. , 1995, Cancer surveys.

[49]  L. Baert,et al.  Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. , 1995, The Journal of urology.

[50]  Y. Ohashi,et al.  Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer , 2005, The Prostate.

[51]  F. Labrie,et al.  Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist , 1994 .

[52]  T. Mate,et al.  Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[53]  A. Hanlon,et al.  Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. , 1997, International journal of radiation oncology, biology, physics.

[54]  D. Grignon,et al.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Chin,et al.  CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. , 1999, Urology.

[56]  J. Goméz,et al.  Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. , 1996, The American journal of surgical pathology.

[57]  G. Muto,et al.  Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. , 2002, Journal of clinical pathology.

[58]  J Gabbay,et al.  'Early warning systems' for identifying new healthcare technologies. , 1999, Health technology assessment.

[59]  J. Damber,et al.  Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. , 1998, The Journal of urology.

[60]  L. Baert,et al.  Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. , 1995 .

[61]  B. Têtu,et al.  Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[62]  J. Beck,et al.  Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). , 2005, International journal of radiation oncology, biology, physics.

[63]  T. Tammela,et al.  Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. , 2004, The Journal of urology.

[64]  G. Hanks,et al.  Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[65]  G. Murphy,et al.  Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. , 1996, European urology.

[66]  A. Fortin,et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[67]  C. Begg,et al.  Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. , 1997, British journal of urology.

[68]  G. Murphy,et al.  Adjuvant therapy for localized prostate cancer , 1993, Cancer.

[69]  D. Wood,et al.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. , 2002, The Journal of urology.

[70]  L. Baert,et al.  Neoadjuvant treatment before radical prostatectomy decreases the number of positive margins in cT2-cT3 but has no impact on PSA progression or survival in cT2-T3 , 1998 .

[71]  D. Cook,et al.  Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. , 1999, Health technology assessment.

[72]  J. Hugosson,et al.  Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy. , 1999, Urology.

[73]  G. Murphy,et al.  Evaluation of adjuvant estramustine phosphate, cyclophosphamide and observation only for node‐positive patients following radical prostatectomy and definitive irradiation , 1996, The Prostate.

[74]  H. Poppel.  Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out. , 2001 .

[75]  T. Matsuda,et al.  Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. , 2004, Japanese journal of clinical oncology.

[76]  C. D’Este,et al.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.

[77]  L. Weissbach,et al.  Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. , 2004, European urology.

[78]  P. Bonnet,et al.  Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. , 2002, Clinical prostate cancer.

[79]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[80]  Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer. , 1992, British journal of urology.

[81]  P. Rubin,et al.  Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. , 1995, International journal of radiation oncology, biology, physics.

[82]  E. Horwitz,et al.  Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[83]  R. Stock,et al.  Prostate brachytherapy: treatment strategies. , 1999, The Journal of urology.

[84]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[85]  M. Bolla.  Adjuvant Hormonal Treatment with Radiotherapy for Locally Advanced Prostate Cancer , 1998, European Urology.

[86]  Y. Homma,et al.  Endocrine therapy with or without radical prostatectomy for T1b‐T3N0M0 prostate cancer , 2004, International journal of urology : official journal of the Japanese Urological Association.

[87]  G. Lockwood,et al.  Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[88]  A. Pollack,et al.  Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. , 1999, International journal of radiation oncology, biology, physics.

[89]  M. Ghoneim,et al.  Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. , 1997, The Journal of urology.

[90]  T. Tammela,et al.  Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. , 2002, The Journal of urology.

[91]  F. Debruyne,et al.  Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma , 1997 .

[92]  M. Wirth,et al.  Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[93]  M. Meng,et al.  Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. , 2002, Seminars in urologic oncology.

[94]  Y. Homma,et al.  A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5‐year follow‐up , 2003, BJU international.

[95]  H. Brereton,et al.  Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy , 1996, The Prostate.

[96]  A. Zlotta,et al.  4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer , 2000, European Urology.

[97]  S. Feigenberg,et al.  Long‐term hormone therapy and radiation is cost‐effective for patients with locally advanced prostate carcinoma , 2006, Cancer.

[98]  E. Crawford,et al.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. , 1998, Urology.

[99]  M. Wirth,et al.  Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. , 2004, The Journal of urology.

[100]  O. Yoshida,et al.  A prospective randomized trial for treating stages B2 and C prostate cancer: radical surgery or irradiation with neoadjuvant endocrine therapy. , 1994, Japanese journal of clinical oncology.

[101]  S. Goldenberg,et al.  Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group. , 1998, The Journal of urology.

[102]  D. Siders,et al.  Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[103]  Y. Homma,et al.  Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation , 1999, International journal of urology : official journal of the Japanese Urological Association.

[104]  D. Prezioso,et al.  Neoadjuvant Hormone Treatment with Leuprolide Acetate Depot 3.75 mg and Cyproterone Acetate, before Radical Prostatectomy: A Randomized Study , 2004, Urologia Internationalis.